Exploring DRD4 and its interaction with SLC6A3 as possible risk factors for adult ADHD: A meta-analysis in four European populations
Attention‐deficit hyperactivity disorder (ADHD) is a common behavioral disorder affecting about 4–8% of children. ADHD persists into adulthood in around 65% of cases, either as the full condition or in partial remission with persistence of symptoms. Pharmacological, animal and molecular genetic stud...
Saved in:
Published in | American journal of medical genetics. Part B, Neuropsychiatric genetics Vol. 156B; no. 5; pp. 600 - 612 |
---|---|
Main Authors | , , , , , , , , , , , , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Hoboken
Wiley Subscription Services, Inc., A Wiley Company
01.07.2011
Wiley-Liss |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Attention‐deficit hyperactivity disorder (ADHD) is a common behavioral disorder affecting about 4–8% of children. ADHD persists into adulthood in around 65% of cases, either as the full condition or in partial remission with persistence of symptoms. Pharmacological, animal and molecular genetic studies support a role for genes of the dopaminergic system in ADHD due to its essential role in motor control, cognition, emotion, and reward. Based on these data, we analyzed two functional polymorphisms within the DRD4 gene (120 bp duplication in the promoter and 48 bp VNTR in exon 3) in a clinical sample of 1,608 adult ADHD patients and 2,352 controls of Caucasian origin from four European countries that had been recruited in the context of the International Multicentre persistent ADHD CollaboraTion (IMpACT). Single‐marker analysis of the two polymorphisms did not reveal association with ADHD. In contrast, multiple‐marker meta‐analysis showed a nominal association (P = 0.02) of the L‐4R haplotype (dup120bp‐48bpVNTR) with adulthood ADHD, especially with the combined clinical subtype. Since we previously described association between adulthood ADHD and the dopamine transporter SLC6A3 9R‐6R haplotype (3′UTR VNTR‐intron 8 VNTR) in the same dataset, we further tested for gene × gene interaction between DRD4 and SLC6A3. However, we detected no epistatic effects but our results rather suggest additive effects of the DRD4 risk haplotype and the SLC6A3 gene. © 2011 Wiley‐Liss, Inc. |
---|---|
Bibliography: | Obra Social - Fundació "La Caixa" - No. 2007-2010 GK Emotions How to cite this article: Sánchez-Mora C, Ribasés M, Casas M, Bayés M, Bosch R, Fernàndez-Castillo N, Brunso L, Jacobsen KK, Landaas ET, Lundervold AJ, Gross-Lesch S, Kreiker S, Jacob CP, Lesch K-P, Buitelaar JK, Hoogman M, Kiemeney LALM, Kooij JJS, Mick E, Asherson P, Faraone SV, Franke B, Reif A, Johansson S, Haavik J, Ramos-Quiroga JA, Cormand B. 2011. Exploring DRD4 and its interaction with SLC6A3 as possible risk factors for adult ADHD: A meta-analysis in four European populations. Am J Med Genet Part B 156:600-612. Subdirecció General de Drogodependències, Departament de Salut, and Pla Director de Salut Mental i Addiccions, Catalonia Government (Generalitat de Catalunya) DFG - No. RE1632/1-5; No. KFO 125 SFB TRR 58/A1,5; No. Z02; No. GRK 1156 BMBF - No. 01GV0605 istex:475FE0282228F29A54CA504B56021F92A94B3A55 ark:/67375/WNG-77VMZ0GL-8 EC - No. NEWMOOD LSHM-CT-2003-503474 Barbara Franke, Andreas Reif, Stefan Johansson, Jan Haavik, Josep Antoni Ramos-Quiroga, and Bru Cormand contributed equally to this study. The National Research Network for ADHD Western Norway Regional Health Authority The University of Bergen "Instituto de Salud Carlos III-FIS," Spain - No. PI040524 PI041267; No. PI080519 Hersenstichting Nederland (Fonds Psychische Gezondheid) Research Council of Norway ArticleID:AJMG31202 Conflict of interest: Netherlands: In the past 3 years, Jan K. Buitelaar has been a consultant to/member of advisory board of and/or speaker for Janssen Cilag BV, Eli Lilly, Bristol-Myer Squibb, Organon/Shering Plough, UCB, Shire, Medice, and Servier. He is not an employee of any of these companies. He is not a stock shareholder of any of these companies. He has no other financial or material support, including expert testimony, patents or royalties. Sandra Kooij has received research grants from Janssen BV en Shire, and is on the speaker's bureau of Janssen and Eli Lilly. Martine Hoogman, Lambertus Kiemeney, and Barbara Franke declare no conflicts of interest. Norway: Jan Haavik has been a consultant for Janssen Cilag and Novartis. Authors from Germany and Spain declare no conflicts of interest. "Fundació La Marató de TV3" - No. 092330/31 "Agència de Gestió d'Ajuts Univeristaris i de Recerca-AGAUR" - No. 2009SGR-00971 as possible risk factors for adult ADHD: A meta‐analysis in four European populations. Am J Med Genet Part B 156:600–612. Netherlands Barbara Franke, Andreas Reif, Stefan Johansson, Jan Haavik, Josep Antoni Ramos‐Quiroga, and Bru Cormand contributed equally to this study. Norway Conflict of interest and its interaction with Jan Haavik has been a consultant for Janssen Cilag and Novartis. Authors from Germany and Spain declare no conflicts of interest. How to cite this article: Sánchez‐Mora C, Ribasés M, Casas M, Bayés M, Bosch R, Fernàndez‐Castillo N, Brunso L, Jacobsen KK, Landaas ET, Lundervold AJ, Gross‐Lesch S, Kreiker S, Jacob CP, Lesch K‐P, Buitelaar JK, Hoogman M, Kiemeney LALM, Kooij JJS, Mick E, Asherson P, Faraone SV, Franke B, Reif A, Johansson S, Haavik J, Ramos‐Quiroga JA, Cormand B. 2011. Exploring DRD4 SLC6A3 In the past 3 years, Jan K. Buitelaar has been a consultant to/member of advisory board of and/or speaker for Janssen Cilag BV, Eli Lilly, Bristol‐Myer Squibb, Organon/Shering Plough, UCB, Shire, Medice, and Servier. He is not an employee of any of these companies. He is not a stock shareholder of any of these companies. He has no other financial or material support, including expert testimony, patents or royalties. Sandra Kooij has received research grants from Janssen BV en Shire, and is on the speaker's bureau of Janssen and Eli Lilly. Martine Hoogman, Lambertus Kiemeney, and Barbara Franke declare no conflicts of interest. ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 |
ISSN: | 1552-4841 1552-485X 1552-485X |
DOI: | 10.1002/ajmg.b.31202 |